This also indicated that there was no difference in clinicopathological invasiveness between FNMTC and SNMTC from a genetic perspective, while researchers generally believed that BRAF V600E can drive the growth of PTC through the mitogen-activated protein kinase (MAPK) pathway, and TERT promoter mutation might have a similar effect (25–30). This evidence concerns the gene WNK2 and familial papillary or follicular thyroid carcinoma.